Clinical Trial Update: Platelet Response to Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura

View source ↗

Summary

The update reports on platelet response to caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura, based on a completed clinical study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Thrombotic Thrombocytopenic Purpura

Drugs mentioned

• Caplacizumab (caplacizumab)

Snippet

Sponsor: University of Cologne | Conditions: Acquired Thrombotic Thrombocytopenic Purpura | Status: COMPLETED